Results for multicenter translation from English to Romanian

single center multicenter study
studiu monocentric

the efficacy of infliximab was assessed in two multicenter, randomised, double blind studies:
psoriazis eficacitatea infliximabului a fost evaluată în două studii multicentrice randomizate dublu- orb:

most of the primary immunogenicity studies were conducted as randomized, controlled, multicenter, clinical trials.
majoritatea studiilor referitoare la imunogenicitatea primară au fost organizate ca studii randomizate, controlate, multicentrice.

study 2 was a randomized, controlled, multicenter study comparing the zevalin therapeutic regimen versus treatment with rituximab.
studiul 2 a fost un studiu randomizat, controlat, multicentric, care a comparat schema terapeutică cu zevalin cu tratamentul cu rituximab.

the immunogenicity of prevenar has been investigated in an open-label, multicenter study in 49 infants with sickle cell disease.
imunogenitatea prevenar a fost investigată în cadrul unui studiu deschis, multicentric, pe 49 de sugari cu drepanocitoză.

paediatric patients the safety and efficacy of cancidas was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials.
9 copii şi adolescenţi siguranţa şi eficacitatea administrării cancidas au fost evaluate la copii şi adolescenţi cu vârsta de 3 luni până la 17 ani în două studii clinice prospective, multicentrice.

the efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: spirit and express.
eficacitatea infliximabului a fost evaluată în două studii multicentrice randomizate dublu-orb: spirit şi express.

start was a randomised, multicenter, double-blind, 3-arm, parallel-group safety study.
start a fost un studiu randomizat, multicentric, dublu-orb, cu 3 braţe, pe grupe paralele, pentru evaluarea siguranţei.

efficacy and safety were assessed in two multicenter, double-blind, placebo-controlled studies in patients with active psoriatic arthritis.
eficacitatea şi siguranţa au fost studiate în două studii multicentrice dublu-orb, placebo controlate, la pacienţi cu artrită psoriazică activă.

voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic hsct recipients without prior proven or probable ifi.
voriconazol a fost comparat cu itraconazol ca profilaxie primară într-un studiu deschis, comparativ, multicentric, efectuat la pacienţii adulţi şi adolescenţi cu transplant alogenic de celule stem hematopoietice fără ifi anterior dovedite sau probabile.

assessment of the pharmacokinetics, safety, tolerability, and virologic response of reyataz oral powder was based on data from two open-label, multicenter clinical trials.
evaluarea farmacocineticii, a siguranţei, tolerabilităţii şi răspunsului virusologic la tratamentul cu reyataz pulbere orală a avut la bază datele din două studii clinice multiceentrice, cu design deschis.

an international, multicenter, randomized, open-label, comparative phase 3 efficacy and safety study was conducted in newly diagnosed ph+ cp cml patients.
un studiu comparativ de fază 3, deschis, randomizat, multicentric, internaţional, privind eficacitatea şi siguranţa a fost efectuat la pacienţii nou diagnosticaţi cu fc a lmc ph+.

the safety and efficacy of oncaspar was evaluated in an open-label, multicenter, randomized, active-controlled study (study 1).
siguranţa şi eficacitatea oncaspar au fost evaluate într-un studiu deschis, multicentric, randomizat, cu control activ (studiul 1).

leflunomide was studied in a single multicenter, randomized, double-blind, active-controlled trial in 94 patients (47 per arm) with polyarticular course juvenile rheumatoid arthritis.
leflunomida a fost evaluată într-un singur studiu multicentric, randomizat, dublu-orb, cu comparator activ, cu 94 de pacienţi (47 în fiecare braţ) cu artrită reumatoidă juvenilă cu evoluţie poliarticulară.